<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252521</url>
  </required_header>
  <id_info>
    <org_study_id>66175679-514.04.01</org_study_id>
    <nct_id>NCT04252521</nct_id>
  </id_info>
  <brief_title>Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Migraine</brief_title>
  <official_title>Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adiyaman University Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adiyaman University Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute headache is one of the most common reasons for presentation to the emergency department
      (ED), accounting for 2-3% of all emergency visits. Migraine is a disorder of the central
      nervous system characterized by a moderate or severe headache, which is generally associated
      with nausea and/or sensitivity to light and sound, interfering with daily activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objective: The objective of this study is to determine the analgesic efficacy and
      safety of intravenous, single-dose metoclopramide versus dexketoprofen trometamol versus
      metoclopramide+ dexketoprofen trometamol in patients presenting with acute migraine attack to
      the emergency department (ED).

      Methods of Measurements:

      This single-center, randomized, double-blind study will be conducted in a tertiary care ED.
      Eligible patients who met the migraine criteria of the International Headache Society will be
      randomized to receive 10 mg intravenous metoclopramide, 50 mg intravenous dexketoprofen
      trometamol, or 50 mg dexketoprofen trometamol + 10 mg metoclopramide.

      Subjects reported pain intensity on both a 100-mm visual analogue scale (VAS) (limited by 'no
      pain' and 'the worst pain') will be used for pain measurement at baseline, after 15 and 30
      min. The primary outcome measure is the changes in the VAS scores at the 15th and 30th
      minutes of treatment. The secondary outcome measures are the presence of adverse effects and
      the requirement of rescue medicine.

      Primary Data Analysis:

      The study was planned as a superiority trial. The difference in the VAS values between the
      groups was assumed to detect 21.4 mm and the standard deviation (SD) value as 2.8 mm, and
      thus the minimum required the number of patients for each group was calculated as 27 at the
      alpha-critical value of 0.05 and power of 80%. All the analyses were implemented according to
      the intention to treat analysis. Differences between time intervals within groups and between
      groups and statistical significance were expressed by 95% confidence intervals (95% CI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Actual">January 3, 2020</completion_date>
  <primary_completion_date type="Actual">January 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the intensity of pain</measure>
    <time_frame>15 minutes and 30 minutes after the study drug administered</time_frame>
    <description>Pain intense will be measured by 100 mm visual analog scale (Zero; no pain and 100 mm; the worst pain) after 15th and 30th minutes later after the study drug administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 minutes after</time_frame>
    <description>30 minutes after the study drug administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need to rescue medication</measure>
    <time_frame>30 minutes after</time_frame>
    <description>30 minutes after the study drug administered</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>metoclopramide+ dexketoprofen trometamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg metoclopramide+ 50 mg dexketoprofen trometamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg metoclopramide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexketoprofen trometamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg dexketoprofen trometamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>10 mg Metpamid in 100 ml normal saline solution</description>
    <arm_group_label>metoclopramide</arm_group_label>
    <other_name>Metpamid (metoclopramide)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexketoprofen trometamol</intervention_name>
    <description>50 mg dexketoprofen trometamol in 100 ml normal saline solution</description>
    <arm_group_label>dexketoprofen trometamol</arm_group_label>
    <other_name>Metadem (dexketoprofen trometamol)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide+dexketoprofen trometamol</intervention_name>
    <description>10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution</description>
    <arm_group_label>metoclopramide+ dexketoprofen trometamol</arm_group_label>
    <other_name>Metpamid+Metadem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients aged 18 and over with acute headache who met the diagnostic criteria of the
        International Headache Association (9) for the diagnosis of migraine

        Exclusion Criteria:

          -  Patients who refused to participate in the study

          -  Patients that took any analgesic medication within six hours before presentation to ED
             Patients with any additional organic pathology (e.g., hypertension, hypoglycemia,
             chronic kidney failure, and intracranial masses) pregnant women hemodynamically
             unstable patients patients with an allergy to the drugs used in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umut Gülaçtı</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adiyaman University of Medical Faculty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adiyaman University Research Hospital</name>
      <address>
        <city>Adıyaman</city>
        <state>Central</state>
        <zip>02000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. Ann Emerg Med. 2014 Nov;64(5):526-532.e1. doi: 10.1016/j.annemergmed.2014.03.017. Epub 2014 May 10.</citation>
    <PMID>24818542</PMID>
  </reference>
  <reference>
    <citation>Yang B, Xu Z, Chen L, Chen X, Xie Y. The efficacy of dexketoprofen for migraine attack: A meta-analysis of randomized controlled studies. Medicine (Baltimore). 2019 Nov;98(46):e17734. doi: 10.1097/MD.0000000000017734.</citation>
    <PMID>31725614</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 1, 2020</last_update_submitted>
  <last_update_submitted_qc>February 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Adiyaman University Research Hospital</investigator_affiliation>
    <investigator_full_name>Umut Gulacti</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

